Patent 11266666 was granted and assigned to Gilead Sciences on March, 2022 by the United States Patent and Trademark Office.
Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: